Methotrexate for maintenance of remission in Crohn's disease

Scolaris Content Display Scolaris Content Display

Ir a:

Figure 1

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

Figure 2

Forest plot of comparison: 1 Methotrexate versus Placebo, outcome: 1.1 Proportion of patients maintaining clinical remission.

Figure 3

Forest plot of comparison: 2 Methotrexate versus 6‐MP, outcome: 2.1 Proportion of patients maintaining clinical remission.

Analysis 1.1

Comparison 1 Methotrexate versus placebo, Outcome 1 Proportion of patients maintaining clinical remission.

Analysis 2.1

Comparison 2 Methotrexate versus 6‐MP, Outcome 1 Proportion of patients maintaining clinical remission.

Analysis 3.1

Comparison 3 Methotrexate versus 5‐ASA, Outcome 1 Proportion of patients maintaining clinical remission.

Comparison 1. Methotrexate versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Proportion of patients maintaining clinical remission Show forest plot	2	98	Odds Ratio (M‐H, Fixed, 95% CI)	3.11 [1.31, 7.41]

Comparison 1. Methotrexate versus placebo

Comparison 2. Methotrexate versus 6‐MP

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Proportion of patients maintaining clinical remission Show forest plot	2	50	Odds Ratio (M‐H, Fixed, 95% CI)	2.63 [0.74, 9.37]

Comparison 2. Methotrexate versus 6‐MP

Comparison 3. Methotrexate versus 5‐ASA

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Proportion of patients maintaining clinical remission Show forest plot	1	13	Odds Ratio (M‐H, Fixed, 95% CI)	5.67 [0.19, 169.53]

Comparison 3. Methotrexate versus 5‐ASA